Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | KHK | P50053 | 12/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918969 | 0.89 | KDM4E (0.39) | KDM4ELMNAALDH1A1L3MBTL1MEN1 | |
| SCHEMBL2249138 | 0.88 | KDM4E (0.42) | KDM4ELMNAALDH1A1L3MBTL1MEN1 | |
| SCHEMBL2246653 | 0.87 | GSK3B (0.34) | KDM4ELMNAALDH1A1MEN1HPGD | |
| SCHEMBL2247032 | 0.86 | GSK3B (0.39) | KDM4ELMNAALDH1A1L3MBTL1MEN1 | |
| SCHEMBL17012169 | 0.85 | KDM4E (0.36) | KDM4ELMNAALDH1A1L3MBTL1MEN1 | |
| SCHEMBL2243917 | 0.83 | JAK3 (0.44) | KDM4ELMNAALDH1A1L3MBTL1MEN1 | |
| SCHEMBL17012170 | 0.79 | KDM4E (0.36) | KDM4ELMNAALDH1A1L3MBTL1MEN1 | |
| SCHEMBL2252780 | 0.76 | JAK3 (0.44) | KDM4ELMNAALDH1A1L3MBTL1MEN1 | |
| SCHEMBL1919395 | 0.75 | GSK3B (0.48) | KDM4ETDP1MAPT | |
| SCHEMBL1919317 | 0.74 | KDM4E (0.41) | KDM4ELMNAALDH1A1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326639-B1 | SUBSTITUTED PYRIDINES AND ITS USE AS GSK3 INHIBITORS | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| EP-2326639-B1 | SUBSTITUTED PYRIDINES AND ITS USE AS GSK3 INHIBITORS | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-8664246-B2 | Substituted pyridines, and use thereof as GSK3 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-8664246-B2 | Substituted pyridines, and use thereof as GSK3 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20110190316-A1 | Substituted pyridines, and use thereof as Gsk3 inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190316-A1 | Substituted pyridines, and use thereof as Gsk3 inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-04 | — | — | US | disclosed |
| WO-2010012398-A1 | SUBSTITUTED PYRIDINES, AND USE THEREOF AS GSK3 INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190316-A1 | Substituted pyridines, and use thereof as Gsk3 inhibitors | GSK3B, GSK3A, GSKIP | KDM4E 620/4885LMNA 1499/4885ALDH1A1 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.